Department of Biomorphological and Functional Sciences, Federico II University of Naples, Via Pansini 5, 80131 Naples, Italy
Institute of Biostructures and Bioimages, National Council of Research (CNR), Naples, Italy
Institute of Scientific Care and Research (IRCCS), Institute of Nuclear Diagnostics Foundation (SDN), Naples, Italy
References: Davies, L., Welch, H.G., Increasing incidence of thyroid cancer in the United States, 1973-2002 (2006) J Am Medical Assoc, 295, pp. 2164-216
Schlumberger MJ Diagnostic follow-up of well differentiated thyroid carcinoma: historical perspective and current status. J Endocrinol Invest 1999
22:3-7Joensuu, H., Ahinen, A., Imaging of metasstases of thyroid carcinoma with fluorine-18-fluorodeoxyglucose (1987) J Nuclear Med, 28, pp. 910-914
Feine, U., Lietznmayer, R., Hankie, J.P., Wöhrle, H., Müller-Schauenburg, W., 18FDG whole-body PET in differentiated thyroid carcinoma. Flipflop in uptake patterns of 18FDG and 131I] (1995) Nuklearmedizine, 34, pp. 127-134. , German
Feine, U., Lietzenmayer, R., Hanke, J.P., Fluorine-18-FDG and iodine-131-iodide uptake in thyroid cancer (1996) J Nuclear Med, 37, pp. 1468-1472
Grunwald, F., Schomburg, A., Bender, H., Held, J., Wöhrle, H., Müller-Schauenburg, W., Fluorine-18 fluorodeoxyglucose positron emission tomography in the follow-up of differentiated thyroid cancer (1996) Eur J Nuclear Med, 23, pp. 312-319
Cohen, M.S., Arslan, N., Dehdashti, F., Doherty, G.M., Lairmore, T.C., Brunt, L.M., Risk of malignancy in thyroid incidentalomas identified by fluorodeoxyglucose-positron emission tomography (2001) Surgery, 1309, pp. 41-46
Ramos, C.D., Chisin, R., Yeung, H.W., Larson, S.M., Macapinlac, H.A., Incidental focal thyroid uptake on FDG positron emission tomographic scans may represent second primary tumor (2001) Clin Nucl Med, 26, pp. 193-197
Wolf, G., Aigner, R.M., Schaffler, G., Schwarz, T., Krippl, P., Pathology results in [18F]fluorodeoxyglucose positron emission tomography of the thyroid gland (2003) Nucl Med Commun, 24, pp. 1225-1230
Yasuda, S., Shohtsu, A., Ide, M., Takagi, S., Takanashi, W., Suzuki, Y., Chronic thyroiditis:diffuse uptake of FDG at PET (1998) Radiology, 207, pp. 775-778
Davis, P.W., Perrier, N.D., Adler, L., Levine, E.A., Incidental thyroid carcinoma identified by positron emission tomography scanning obtained for metastatic evaluation (2001) Am Surg, 67, pp. 582-584
King, D.L., Stack, B.C., Spring, P.M., Walker, R., Bodenner, D.L., Incidence of thyroid carcinoma in fluorodeoxyglucose positron emission tomography-positive thyroid incidentalomas (2007) Otolaryngol Head Neck Surg, 137, pp. 400-404
Kang, K.W., KIM, S.K., Kang, H.S., Lee, E.S., Sim, J.S., Lee, I.G., Prevalence and risk of cancer of focal thyroid incidentaloma identified by 18-F-fluorodeoxyglucose postiron emission tomography for metastasi evaluation anc cancer screening in healthy subjects (2003) J Clin Endocrinol Metabol, 88, pp. 4100-4104
Kwak, J.Y., Kim, E.K., Yun, M., Cho, A., Kim, M.J., Son, E.J., Oh, K.K., Thyroid Incidentalomas Identified by 18F-FDG PET:Sonographic Correlation (2008) AJR, 191, pp. 598-603
Are, C., Hsu, J.F., Schoder, H., Shah, J.P., Larson, S.M., Shaha, A.R., FDG-PET detected thyroid incidentalomas:need for further investigation? (2007) Ann Surg Oncol, 14, pp. 239-247
Heusner, T.A., Hahn, S., Hamami, M.E., Kögel, S., Forsting, M., Bockisch, A., Incidental head and neck (18)F-FDG uptake on PET/CT without corresponding morphological lesion:early predictor of cancer development? (2009) Eur J Nucl Med Mol Imaging, 36, pp. 1397-1406
Alexander, E.K., Heering, J.P., Benson, C.B., Frates, M.C., Doubilet, P.M., Cibas, E.S., Assessment of nondiagnostic ultrasound-guided fine needle aspirations of thyroid nodules (2002) J Clin Endocrinol Metab, 87, pp. 4924-4927
Uematsu, H., Sadato, N., Ohtsubo, T., Tsuchida, T., Nakamura, S., Sugimoto, K., Fluorine-18-fluorodeoxyglucose PET versus thallium-201 scintigraphy evaluation of thyroid tumors (1998) J Nucl Med, 39, pp. 453-459
Zhuang, H., Kumar, R., Mandel, S., Alavi, A., Investigation of thyroid, head, and neck cancers with PET (2004) Radiol Clin North Am, 42, pp. 1101-1111
Adler, L.P., Bloom, A.D., Positron emission tomography of thyroid masses (1993) Thyroid, 3, pp. 195-200
Bloom, A.D., Adler, L.P., Shuck, J.M., Determination of malignancy of thyroid nodules with positron emission tomography (1993) Surgery, 114, pp. 728-734
Smith, R.B., Robinson, R.A., Hoffman, H.T., Graham, M.M., Preoperative FDG-PET imaging to assess the malignant potential of follicular neoplasms of the thyroid (2008) Otolaryngol Head Neck Surg, 138, pp. 101-106
Hales, N.W., Krempl, G.A., Medina, J.E., (2008) Is there a role for fluorodeoxyglucose positron emission tomography/computed tomography in cytologically indeterminate thyroid nodules? American Journal of Otolaryngology - Head and Neck Medicine and Surgery, 29, pp. 113-118
Sebastianes FM, Cerci JJ, Zanoni PH, Soares J Jr., Chibana LK, Tomimori EK et al. Role of 18F-fluorodeoxyglucose positron emission tomography in preoperative assessment of cytologically indeterminate thyroid nodules. The J Clin Endocrinol Metabol 2007
92:4485-8Al-Zahrani, A.S., Abouzied, M.E.M., Salam, S.A., Mohamed, G., Rifai, A., Sugair, A.A., The role of F-18-fluorodeoxyglucose positron emission tomography in the postoperative evaluation of differentiated thyroid cancer (2008) Eur J Endocrinol, 158, pp. 683-689
Jeong, H.S., Baek, C.H., Son, Y.I., Choi, J.Y., Kim, H.J., Ko, Y.H., Integrated 18F-FDG PET/CT for the initial evaluation of cervical node level of patients with papillary thyroid carcinoma:comparison with ultrasound and contrast-enhanced CT (2006) Clin Endocrinol, 65, pp. 402-407
Dietlein, M., Scheidhauer, K., Voth, E., Theissen, P., Schicha, H., Fluorine-18 fluorodeoxyglucose positron emission tomography and iodine-131 whole-body scintigraphy in the follow-up of differentiated thyroid cancer (1997) Eur J Nucl Med, 24, pp. 1342-1348
Grünwald, F., Schomburg, A., Bender, H., Klemm, E., Menzel, C., Bultmann, T., Fluorine-18 fluorodeoxyglucose positron emission tomography in the follow-up of differentiated thyroid cancer (1996) Eur J Nucl Med, 23, pp. 312-319
Chung, J.K., So, Y., Lee, J.S., Choi, C.W., Lim, S.M., Lee, D.S., Value of FDG PET in papillary thyroid carcinoma with negative 131I wholebody scan (1999) J Nucl Med, 40, pp. 986-992
Alnafisi, N.S., Driedger, A.A., Coates, G., Moote, D.J., Raphael, S.J., FDG PET of recurrent or metastatic 131I-negative papillare thyroid carcinoma (2000) J Nucl Med, 41, pp. 1010-1015
Wang, W., Macapinlac, H., Larson, S.M., Yeh, S.D., Akhurst, T., Finn, R.D., 18F]-2-fluoro-2-deoxy-D glucose positron emission tomography localizes residual thyroid cancer in patients with negative diagnostic (131)I whole body scans and elevated serum thyroglobulin levels (1999) J Clin Endocrinol Metabol, 84, pp. 2291-2302
Schluter, B., Bohuslavizki, K.H., Beyer, W., Buchert, R., Clausen, M., Impact of FDG PET on patients with differentiated thyroid carcinoma who present with elevated thyroglobulin and negative 131-I scan (2001) J Nucel Med, 42, pp. 71-76
Helal, B.O., Merlot, P., Toubert, M.E., Franc, B., Schvartz, C., Gauthier-Koelesnikov, H., Clinical impact of 18F-FDG PET in thyroid carcinoma patients with elevated thyroglobulin levels and negative 131I scanning results after therapy (2001) J Nucl Med, 42, pp. 1464-1469
Gabriel, M., Froehlich, F., Decristoforo, C., Ensinger, C., Donnemiller, E., von Guggenberg, E., 99mTc-EDDA/HYNIC-TOC and 18F-FDG in thyroid cancer patients with negative 131I whole-body scans (2004) Eur J Nucl Med Mol Imaging, 31, pp. 330-341
Iwata, M., Kasagi, K., Misaki, T., Matsumoto, K., Iida, Y., Ishimori, T., Comparison of whole-body 18F-FDG PET, 99mTc-MIBI SPET, and post-therapeutic 131I-Na scintigraphy in the detection of metastatic thyroid cancer (2004) Eur J Nucl Med Mol Imaging, 31, pp. 491-498
Palmedo, H., Bucerius, J., Joe, A., Strunk, H., Hording, N., Meyka, S., Integrated PET/CT in differentiated thyroid cancer: Diagnostic accuracy and impact on patient management (2006) J Nucl Med, 47, pp. 616-624
Mirallié, E., Guillan, T., Bridji, B., Resche, I., Caroline Rousseau, C., Ansquer, C., Therapeutic impact of 18FDG-PET/CT in the management of iodinenegative recurrence of differentiated thyroid carcinoma (2007) Surgery, 142, pp. 952-958
Freudenberg, L.S., Frilling, A., Kuhl, H., Muller, S.P., Jentzen, W., Bockisch, A., Dual-modality FDG-PET/CT in follow-up of patients with recurrent iodine-negative differentiated thyroid cancer (2007) Eur Radiol, 17, pp. 3139-3147
Grant, C.S., Thompson, G.B., Farley, D.R., Richards, M.L., Mullan, B.P., Hay, I.D., The Value of Positron Emission Tomography in the Surgical Management of Recurrent Papillary Thyroid Carcinoma (2008) World J Surg, 32, pp. 708-715
Finkelstein, S.E., Grigsby, P.W., Siegel, B.A., Dehdashti, F., Moley, J.F., Hall, B.L., Combined [18F]fluorodeoxyglucose positron emission tomography and computed tomography (FDG-PET/CT) for detection of recurrent, 131-I negative thyroid cancer (2008) Ann Surg Oncol, 15, pp. 286-292
Kim, S.J., Lee, T.H., Kim, I.J., Kim, Y.K., Clinical implication of F-18 FDG PET/CT for differentiated thyroid cancer in patients with negative diagnostic iodine-123 scan and elevated thyroglobulin (2009) Eur J Radiol, 70, pp. 17-24
Esteva, D., Muras, M.A., Llamas-Elvira, J.M., Alonso, J., Villar, J.M., Lòpez de la Torre, M., Clinical and pathological factors related to 18F-FDG-PET positivity in the diagnosis of recurrence and/or metastasis in patients with differentiated thyroid cancer (2009) Ann Surg Oncol, 16, pp. 2006-2013
Shammas, A., Degirmenci, B., Mountz, J.M., McCook, B.M., Branstetter, B., Bencherif, B.B., 18-F-FDG PET/CT in patients with suspected recurrent or metastatic well-diffeentiate thyroid cancer (2007) J Nucl Med, 48, pp. 221-226
Giammarile, F., Hafdi, Z., Bournaud, C., Janier, M., Houzard, C., Desuzinges, C., Is [18F]-2-fluoro-2-deoxy-d-gucose (FDG) scintigraphy with non-dedicated positron emission tomography useful in the diagnostic management of suspected metastatic carcinoma in patients with no detectable radioiodine uptake? (2003) Eur J Endocrinol, 149, pp. 293-300
Hooft, L., Hoekstra, O.S., Devillé, W., Lips, P., Teule, G.J.J., Boers, M., Diagnostic accuracy of 18F-fluorodeoxyglucose positron emission tomography in the follow-up of papillary or follicular thyroid cancer (2001) J Clin Endocrinol Metabol, 86, pp. 3779-3786
Davison, J.M., Stocker, D.J., Montilla-Soler, J.L., Jurgens, J.S., Allen, T.W., Holley, T.S., The added benefit of a dedicated neck F-18 FDG PET-CT imaging protocol in patients with suspected recurrent differentiated thyroid carcinoma (2008) Clin Nucl Med, 33, pp. 464-468
Seioh, L., Van nostrano, D., Wartofsky, L., Ousman, Y., Jonklas, J., Butler, C., Utilità of PEET/neck MRI digital fusion images in the management of recurrent or persistent thyroid cancer (2008) Thyroid, 18, pp. 103-111
Zoller, M., Kohlfuerst, S., Igerc, I., Kresnik, E., Gallowitsch, H.J., Gomez, I., Combined PET/CT in the follow-up of differentiated thyroid carcinoma:what is the impact of each modalità ? (2007) Eur J Nucl Med Mol Imaging, 34, pp. 487-495
Nahas, Z., Goldenberg, D., Fakhry, C., Ewertz, M., Zeiger, M., Ladenson, P.W., The role of positron emission tomography/computer tomography in the management of recurrent papillary thyroid carcinoma (2005) Laryngoscope, 115, pp. 237-243
Saab, G., Driedger, A.A., Pavlosky, W., McDonald, T., Wong, C.Y., Yoo, J., Thyroid-stimulating hormone-stimulated fused positron emission tomography/computer tomography in the evaluation of recurrence in 131I-negative papillare thyroid carcinoma (2006) Thyroid, 16, pp. 267-272
Hung, G.U., Lee, K.W., Liao, P.Y., Yang, L.H., Yang, K.T., The influence of I-131 therapy on FDG uptake in differentiated thyroid cancer (2008) Ann Nucl Med, 22, pp. 481-485
Hoie, J., Stenwig, A., Kullmann, G., Lindegaard, M., Distant metastases in papillare thyroid cancer. A review of 91 patients (1988) Cancer, 61, pp. 1-6
Schlumberger, M., Papillary and follicular thyroid carcinoma (1998) New Engl J Med, 338, pp. 297-306
Rivera, M., Ghossein, R.A., Schoder, H., Gomez, D., Larson, S.M., Tuttle, R.M., Histopathologic characterization of radioactive iodine-refractory fluorodeoxyglucose-positron emission tomography-positive thyroid carcinoma (2008) Cancer, 113, pp. 48-56
Matsuzu, K., Segade, F., Matsuzu, U., Carter, A., Bowden, D.W., Terrier, N.D., Differential expression of glucose transporters in normal and pathologic thyroid tissue (2004) Thyroid, 14, pp. 806-812
Schonberger, J., Ruschoff, J., Grimm, D., Marienhagen, J., Rummele, P., Meyringer, R., Glucose transporter 1 gene expression is related to thyroid neoplasms with an unfavorable prognosis:an immunohistochemical study (2002) Thyroid, 12, pp. 747-754
Stokkel, M.P., Duchateau, C.S., Dragoiescu, C., The value of FDG-PET in the follow-up of differentiated thyroid cancena review of the literature. Q (2006) J Nucl Med Mol Imaging, 50, pp. 78-87
Ciampi, R., Vivaldi, A., Romei, C., Del Guerra, A., Salvadori, P., Cosci, A., Expression analysis of facilitative glucose transporters (GLUTs) in human thyroid carcinoma cell lines and primary tumors (2008) Mol Cell Endocrinol, 291, pp. 57-62
Salvatore, B., Paone, G., Klain, M., Storto, G., Nicolai, E., D'Amico, D., Fluorodeoxyglucose positron emission tomography/computed tomography in patients with differentiated thyroid cancer and elevated thyroglobulin after total thyroidectomy and 131-I ablation. Q (2007) J Nucl Med Mol Imaging, 51, pp. 1-7
Wang, W., Larson, S.M., Fazzari, M., Tickoo, S.K., Kolbert, K., Sgouros, G., Prognostic value of 18-F-fluorodeoxyglucose positron emission tomograhy scanning in patients with thyroid cancer (2000) J Clin Endocrinol Metab, 85, pp. 1107-1113
Robbins, R.J., Wan, Q., Grewal, R.K., Reibke, R., Gonen, M., Strauss, H.W., Real time prognosis for metastatic thyroid carcinoma based on FDG-PET scanning (2006) J Clin Endocrinol Metab, 91, pp. 498-505
Schlumberger, M., Baudin, E., Serum thyroglobulin determination in the follow-up of patients with differentiated thyroid carcinoma (1998) Eur J Endocrinol, 138, pp. 249-252
Mian, C., Barollo, S., Pennelli, G., Pavan, N., Rugge, M., Pelizzo, M.R., Molecular characteristics in papillary thyroid cancers (PTCs) with no 131 I uptake (2008) Clin Endocrinol, 68, pp. 108-116
Ricarte-Filho, J.C., Ryder, M., Chitale, D.A., Rivera, M., Heguy, A., Ladanyi, M., Mutational profile of advanced primary and metastatic radioactive iodine-refractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3CA, and AKT1 (2009) Cancer Res, 69, pp. 4885-4893
Simon, D., Körber, C., Krausch, M., Segering, J., Groth, P., Görges, R., Clinical impact of retinoids in redifferentiation therapy of advanced thyroid cancenfinal results of a pilot study (2002) Eur J Nucl Med, 29, pp. 775-782
Gruning, T., Tiepolt, C., Zophel, K., Zophel, K., Bredow, J., Kropp, J., Retinoic acid for redifferentiation of thyroid cancer-does it hold its promise? (2003) Eur J Endocrinol, 148, pp. 395-402
Fernández, C.A., Puig-Domingo, M., Lomeña, F., Estorch, M., Camacho Martí, V., Bittini, A.L., Effectiveness of retinoic acid treatment for redifferentiation of thyroid cancer in relation to recovery of radioiodine uptake (2009) J Endocrinol Invest, 32, pp. 228-233
Kim, W.G., Kim, E.Y., Kim, T.Y., Ryu, J.S., Hong, S.J., Kim, W.B., Redifferentiation therapy with 13-cis retinoic acids in radioiodine-resistant thyroid cancer (2009) Endocr J, 56, pp. 105-112
Teunissen, J.J.M., Kwekkeboom, D.J., Kooij, P.P.M., Bakker, W.H., Krenning, E., Peptide receptor radionuclide therapy for non-radioiodine-avid differentiated thyroid carcinoma (2005) J Nucl Med, 46, pp. 107S-114S
Iten, F., Muller, B., Schindler, C., Rasch, H., Rochlitz, C., Oertli, D., 90Yttrium-DOTA]-TOC Response is associated with survival benefit in iodine-refractory thyroid cancer (2009) Cancer, 115, pp. 2052-2062
ClinicalTrials.gov. Hompepage, , http://clinicaltrials.gov/ct2/info/about, Internet, Available from, cited 2009, Oct 14
Sisson, J.C., Ackermann, R.J., Meyer, M.A., Wahl, R.L., Uptake of 18-fluoro-2-deoxy-Dglucose by thyroid cancer: Implications for diagnosis and therapy (1993) J Clin Endocrinol Metab, 77, pp. 1090-1094
Petrich, T., Börner, A.R., Otto, D., Hofmann, M., Knapp, W.H., Influence of rhTSH on [18F]fluorodeoxyglucose uptake by differentiated thyroid carcinoma (2002) Eur J Nucl Med, 29, pp. 641-647
Moog, F., Linke, R., Manthey, N., Tiling, R., Knesewitsch, P., Tatsch, K., Influence of thyroid-stimulating hormone levels on uptake of FDG in recurrent and metastatic differentiated thyroid carcinoma (2000) J Nucl Med, 41, pp. 1989-1995
van Tol, K.M., Jager, P.L., Piers, D.A., Pruim, J., de Vries, E.G., Dullaart, R.P., Better yield of (18)fluorodeoxyglucose-positron emission tomography in patients with metastatic differentiated thyroid carcinoma during thyrotropin stimulation (2002) Thyroid, 12, pp. 381-387
Chin, B.B., Patel, P., Cohade, C., Ewertz, M., Wahl, R., Ladenson, P., Recombinant human thyrotropin stimulation of fluoro-d-glucose positron emission tomography uptake in well-differentiated thyroid carcinoma (2004) J Clin Endocrinol Metabol, 89, pp. 91-95
Filetti, S., Damante, G., Foti, D., Thyrotropin stimulates glucose transport in cultured rat thyroid cells (1987) Endocrinology, 120, pp. 2576-2581
Hosaka, Y., Tawata, M., Kurihara, A., Ohtaka, M., Endo, T., Onaya, T., The regulation of two distinct glucose transporter (GLUT1 and GLUT4) gene expressions in cultured rat thyroid cells by thyrotropin (1992) Endocrinology, 131, pp. 159-165
Deichen, J.T., Schmidt, C., Prante, O., Maschauer, S., Papadopoulos, T., Kuwert, T., Influence of TSH on uptake of [18F]fluorodeoxyglucose in human thyroid cells in vitro (2004) Eur J Nucl Med Mol Imaging, 31, pp. 507-512
Blaser, D., Maschauer, S., Kuwert, T., Prante, O., In vitro studies on the signal transduction of thyroidal uptake of 18F-FDG and 131I-iodide (2006) J Nucl Med, 47, pp. 1382-1388
Kim, C.H., Yoo, I.R., Chung, Y.A., Park, Y.H., Kim, S.H., Sohn, H.S., Influence of thyroid-stimulating hormone on 18F-fluorodeoxyglucose and 99mTc-methoxyisobutylisonitrile uptake in human poorly differentiated thyroid cancer cells in vitro (2009) Ann Nucl Med, 23, pp. 131-136
Diagnostic value of FDG PET/CT imaging
Patients with differentiated thyroid cancer (DTC) have a relatively good overall prognosis, but 20% of them develop local recurrences and 10% distant metastases with relatively high mortality (8%). The current prognostic systems lack the ability to predict outcome of patients when discovered to harbor metastases years later. The introduction of 18-F-fluoro-deoxyglucose (FDG) positron emission tomography (PET) and PET/computed tomograohy (CT) for evaluating patients with DTC has added new information on the disease. This review will summarize the data published so far on the use of FDG in DTC. The most appropriate indication to FDG-PET/CT is in evaluating patients with high thyroglobulin level during follow-up, mainly when radioiodine whole body scan is negative. In this setting, a high accuracy has been reported leading to change in management of patients. A clear relationship has been demonstrated between FDG-PET/CT accuracy and thyroglobulin level, with better results obtained in thyroid stimulating hormone (TSH) stimulated condition. Moreover, FDG imaging provides potentially relevant information on tumour biology, and scan results may enable to prognostically stratify DTC patients with local or distant recurrences. Based on literature data, FDG-PET/CT does not have routine clinical indication in the initial staging of DTC patients, as well as in evaluating cytologically indeterminated thyroid nodules.
Bruni AC, Bernardi L, Colao R, Rubino E, Smirne N, Frangipane F, Terni B, Curcio SA, Mirabelli M, Clodomiro A, Di Lorenzo R, Maletta R, Anfossi M, Gallo M, Geracitano S, Tomaino C, Muraca MG, Leotta A, Lio SG, Pinessi L, Rainero I, Sorbi S, Nee L, Milan G, Pappata S, Postiglione A, Abbamondi N, Forloni G, St George Hyslop P, Rogaeva E, Bugiani O, Giaccone G, Foncin JF, Spillantini MG, Puccio G * Worldwide distribution of PSEN1 Met146Leu mutation: A large variability for a founder mutation(1002 views) Neurology (ISSN: 0028-3878, 1526-632x, 1526-632xelectronic), 2010 Mar 9; 74(10): 798-806. Impact Factor:8.017 ViewExport to BibTeXExport to EndNote
Hesse B, Tagil K, Cuocolo A, Anagnostopoulos C, Bardies M, Bax J, Bengel F, Busemann Sokole E, Davies G, Dondi M, Edenbrandt L, Franken P, Kjaer A, Knuuti J, Lassmann M, Ljungberg M, Marcassa C, Marie PY, Mckiddie F, O'connor M, Prvuolovich E, Underwood R * 3. 0 T perfusion MR imaging(731 views) Rivista Di Neuroradiologia (ISSN: 1120-9976), 2004; 17(6): 807-812. Impact Factor:0.023 ViewExport to BibTeXExport to EndNote